6533b82ffe1ef96bd1295a49

RESEARCH PRODUCT

Combined pharmacological treatment of heterozygous familial hypercholesterolemia

R. Carmena

subject

DrugCholestyramineBile acidbiologymedicine.drug_classbusiness.industrymedia_common.quotation_subjectnutritional and metabolic diseasesFamilial hypercholesterolemiaMevalonic acidPharmacologymedicine.diseasePharmacological treatmentchemistry.chemical_compoundchemistryHMG-CoA reductasemedicinebiology.proteinbusinessPravastatinmedicine.drugmedia_common

description

Combined therapy of heterozygous familial hypercholesterolemia using a non-systemically acting drug (bile acid sequestrants) and a systemically acting one is frequently employed in clinical practice. A brief review of this topic is presented, with particular emphasis on the use of cholestyramine combined with pravastatin, a new HMG CoA reductase inhibitor.

yearjournalcountryeditionlanguage
1990-01-01
https://doi.org/10.1007/978-94-009-0731-7_83